Vinva Investment Management Ltd Takes Position in Charles River Laboratories International, Inc. $CRL

Vinva Investment Management Ltd acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 3,724 shares of the medical research company’s stock, valued at approximately $583,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rothschild Investment LLC boosted its position in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International in the second quarter worth $29,000. Atlantic Union Bankshares Corp acquired a new position in Charles River Laboratories International during the third quarter worth $31,000. Geneos Wealth Management Inc. boosted its holdings in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Allworth Financial LP grew its position in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CRL. TD Cowen cut their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Argus set a $200.00 target price on Charles River Laboratories International in a research report on Monday, November 17th. Citigroup upped their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a research report on Monday, December 1st. Finally, Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $167.49 on Wednesday. The company has a market cap of $8.25 billion, a P/E ratio of -56.58, a P/E/G ratio of 3.02 and a beta of 1.64. The firm’s fifty day moving average price is $194.09 and its two-hundred day moving average price is $181.23. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. During the same quarter last year, the company posted $2.66 EPS. Charles River Laboratories International’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.